Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.

@article{Zafonte2000CellcycleDI,
  title={Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.},
  author={Brian T. Zafonte and James Hulit and Derek F. Amanatullah and Chris Albanese and C. Wang and E M Rosen and Anne T. Reutens and Joseph A. Sparano and Michael P Lisanti and Richard G. Pestell},
  journal={Frontiers in bioscience : a journal and virtual library},
  year={2000},
  volume={5},
  pages={
          D938-61
        }
}
  • B. ZafonteJ. Hulit R. Pestell
  • Published 1 December 2000
  • Biology, Chemistry, Medicine
  • Frontiers in bioscience : a journal and virtual library
Breast cancer is the most commonly diagnosed cancer in American women. The underlying mechanisms that cause aberrant cell proliferation and tumor growth involve conserved pathways, which include components of the cell cycle machinery. Proto-oncogenes, growth factors, and steroids have been implicated in the pathogenesis of breast cancer. Surgery, local irradiation, and chemotherapy have been the mainstay of treatment for early and advanced stage disease. Potential targets for selective breast… 
View on PubMed
imrpress.com
58 Citations
Highly Influential Citations
2
Background Citations
33
Results Citations
2

Figures and Tables from this paper

58 Citations

Alterations in Cell Cycle Regulatory Genes in Breast Cancer

Understanding the biology of breast cancer may improve the possibility to overcome this pathology and the chance to have strong prognostic and/or predictive markers will be an immensely useful tool to identify patients at higher risk of relapse and to select the most appropriate systemic treatment for individual breast cancer patients.

Nutritional modulation of the cell cycle and breast cancer.

The intersection of epidemiological studies and medical research examining the molecular pathogenesis of cancers imply a role for dietary prevention and intervention in human breast cancer perhaps through altering cell cycle components.

Ubiquitin Signaling in Ovarian Cancer: From Potential to Challenges

  • Sumegha Mitra
  • Biology
    Ovarian Cancer - From Pathogenesis to Treatment
  • 2018
This chapter provides an overview of various components of UPS which are implicated in cancer and regulate ubiquitin-mediated oncogenic signaling in ovarian cancer.

Exploiting the hallmarks of cancer: the future conquest of breast cancer.

Investigation of the Antitumor Effects of Tamoxifen and Its Ferrocene-Linked Derivatives on Pancreatic and Breast Cancer Cell Lines

Two molecules possessing better cytotoxicity compared to their unmodified parent molecule are found while also being able to counter the negative effects of the presence of the GPER1 through the ER-independent mechanism of oxidative stress induction.

BRCA1 gene in breast cancer

Multiple functions of the BRCA1 that may contribute to its tumor suppressor activity are revealed, including roles in: cell cycle progression, several highly specialized DNA repair processes, DNA damage‐responsive cell cycle checkpoints, regulation of a set of specific transcriptional pathways, and apoptosis.

Hedyotis diffusa Willd Inhibits Colorectal Cancer Growth in Vivo via Inhibition of STAT3 Signaling Pathway

It is found that EEHDW reduced tumor volume and tumor weight, but had no effect on body weight gain in CRC mice, demonstrating that EE HDW can inhibit CRC growth in vivo without apparent adverse effect, and suggesting that suppression of the STAT3 pathway might be one of the mechanisms by which EEHDw treats colorectal cancer.

ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1.

The biology of breast carcinoma

The role of several critical genes including estrogen receptor, progesterone receptor, retinoic acid receptor‐β, epidermal growth factor receptor family members, p53, BRCA1, and BRC a2 as risk factors for the development of disease, predictors of prognosis and response to therapy, and as therapeutic targets is focused on.

Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.

Treatment with Nitidine chloride decreased the tumor volume and tumor weight, suggesting that NC inhibits HCC cell growth in vivo, and provides a molecular basis for the antitumor activity of NC.
...

References

SHOWING 1-10 OF 282 REFERENCES

Steroids, growth factors, and cell cycle controls in breast cancer.

The vast clinical literature provides evidence that the major stimulus for growth of breast cancer is estrogen, and treatment with compounds that act via antagonism of estrogen action, i.e., synthetic antiestrogens and perhaps progestins, leads to remission in a high proportion of patients with receptor-positive tumors.

The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?

Researchers must have the opportunity to continue basic tumor biological and molecular research to gain an understanding of the exact molecular targets and mechanisms of antagonist action, however the current political climate in the US hinders such research.

Induction of apoptosis by the tumor suppressor protein BRCA1.

Since a wide variety of human malignancies like breast and ovarian cancers have a decreased ability to undergo apoptosis, this could be due to lack/decreased levels of functional BRCA1 proteins, treatments that are aimed at increasing the apoptotic threshold by BRCa1 gene therapy may have the potential to prevent the progression of thesemalignancies.

Cancer Cell Cycles

Genetic alterations affecting p16INK4a and cyclin D1, proteins that govern phosphorylation of the retinoblastoma protein and control exit from the G1 phase of the cell cycle, are so frequent in human cancers that inactivation of this pathway may well be necessary for tumor development.

Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression.

  • H. PandhaL. Martín N. Lemoine
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
The results of this study, the first targeted gene therapy for breast cancer and the first to use the cytosine deaminase system in human subjects, are encouraging for the development of genetic prodrug activation therapies that exploit the transcriptional profile of cancer cells.

The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.

Reports on homozygous deletion of p16 and p15 genes suggest the value of larger, prospective studies with standardized treatment protocols to definitively establish the prognostic utility of p15/p16 deletions in acute leukemias.

Metastasis-Associated genes and metastatic tumor progression.

A novel gene called mta1 (rat) or MTA1 (human) that appears to be involved in mammary cell motility and growth regulation is identified that may be an example of a gene that regulates highly malignant cellular phenotypes.

Metastasis-Associated genes and metastatic tumor progression.

A novel gene called mta1 (rat) or MTA1 (human) that appears to be involved in mammary cell motility and growth regulation is identified, which may be an example of a gene that regulates highly malignant cellular phenotypes.

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

It is concluded that overexpression of cyclin Dl deregulates cell proliferation and can induce tumorigenic changes in mammary tissues, suggesting that cyclIn Dl indeed plays an important oncogenic role in breast cancer.

Is TP53 dysfunction required for BRCA1-associated carcinogenesis?

...